Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) consisting of the 44-amino acid sequence of human GHRH with a trans-3-hexenoyl group attached to the N-terminus. This modification enhances the peptide’s stability and resistance to dipeptidyl peptidase-4 (DPP-4) degradation. Tesamorelin stimulates the pituitary gland to release growth hormone (GH) in a pulsatile, physiological manner. It is the most extensively studied GHRH analogue and the only one to have received regulatory approval for a specific indication.
Mechanism of Action
GHRH Receptor Activation
Tesamorelin binds to GHRH receptors on somatotroph cells in the anterior pituitary gland, stimulating the release of endogenous growth hormone. This mechanism differs from exogenous GH administration in several important respects:
- Physiological pulsatility: Tesamorelin stimulates GH release in a pulsatile pattern that more closely mimics natural GH secretion
- Preserved feedback regulation: The hypothalamic-pituitary axis remains intact, so GH release is subject to normal feedback inhibition by insulin-like growth factor 1 (IGF-1) and somatostatin
- Tissue selectivity: By stimulating endogenous GH release, tesamorelin may avoid some of the supraphysiological GH levels that can occur with exogenous administration
Downstream Effects
GH release stimulated by tesamorelin leads to:
- Increased hepatic production of IGF-1
- Enhanced lipolysis, particularly of visceral adipose tissue
- Effects on body composition through GH-mediated metabolic pathways
- Maintenance of lean body mass under certain conditions
Key Research
HIV-Associated Lipodystrophy
Tesamorelin received FDA approval (2010) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy - a condition characterised by abnormal fat distribution associated with antiretroviral therapy. The key clinical trials include:
- Phase 3 trials: Randomised, double-blind, placebo-controlled studies in HIV-positive adults with excess abdominal visceral fat
- Researchers observed significant reductions in visceral adipose tissue (VAT) compared to placebo, as measured by CT scan
- Reductions in waist circumference were also reported
- The effects were specific to visceral fat; subcutaneous fat was not significantly affected
- Upon discontinuation, visceral fat tended to return toward baseline levels
These trials established tesamorelin as the first approved therapy specifically targeting HIV-associated lipodystrophy.
Visceral Fat Research
Beyond the HIV lipodystrophy indication, researchers have examined tesamorelin’s effects on visceral fat in broader populations:
- Non-alcoholic fatty liver disease (NAFLD): Researchers have observed that tesamorelin may reduce hepatic fat content. A randomised controlled trial by Stanley et al. (2019) in The Lancet HIV reported reductions in liver fat in HIV-positive individuals with NAFLD
- General visceral adiposity: Some research has explored whether tesamorelin’s visceral fat-reducing effects extend to non-HIV populations with abdominal obesity
- Cardiometabolic risk: Visceral fat is associated with increased cardiometabolic risk. Researchers have examined whether tesamorelin-mediated visceral fat reduction translates to improvements in metabolic markers
Growth Hormone Secretion
Research into tesamorelin as a tool for understanding and modulating GH secretion:
- Studies have characterised the dose-response relationship between tesamorelin and GH release
- Researchers have observed that tesamorelin maintains pulsatile GH patterns even with chronic administration
- The peptide’s effects on IGF-1 levels have been well characterised in clinical studies
Cognitive Research
Emerging research has explored potential effects of GHRH analogues on cognitive function:
- Some studies have reported modest improvements in cognitive measures in older adults receiving GHRH analogues
- The relationship between GH/IGF-1 axis function and cognitive ageing is an active area of investigation
- These findings are preliminary and require further study
Pharmacological Profile
- Route: Subcutaneous injection
- Dosing frequency: Once daily
- Half-life: Approximately 20-30 minutes (though effects are sustained through downstream GH and IGF-1 pathways)
- IGF-1 elevation: Tesamorelin increases IGF-1 levels within physiological ranges
- Effect on glucose: Unlike exogenous GH, tesamorelin does not appear to significantly worsen glycaemic control at standard doses
Australian Research Context
Tesamorelin (brand name Egrifta) is approved by the TGA for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy. It is classified as a Schedule 4 (Prescription Only) medicine in Australia.
Researchers interested in tesamorelin should note that its approved indication is specific to HIV-associated lipodystrophy. Off-label use or use outside the approved indication falls outside the scope of TGA approval and should be discussed with a qualified healthcare professional.
Research Limitations
- The approved indication is narrow (HIV-associated lipodystrophy)
- Evidence for visceral fat reduction in non-HIV populations is limited
- Long-term safety data beyond two years is relatively limited
- Visceral fat rebound upon discontinuation has been observed
- The peptide requires daily subcutaneous injection
- Effects on hard clinical endpoints (cardiovascular events, mortality) have not been established
Related Compounds
- CJC-1295/Ipamorelin - Another growth hormone secretagogue combination
- MOTS-c - A mitochondrial-derived peptide studied in metabolic research
- GLP-1 Peptides - Overview of GLP-1 receptor agonist research
- Retatrutide - A triple agonist studied in metabolic and obesity research
For research literacy and educational purposes only. This content does not constitute medical advice or therapeutic recommendation. Consult a qualified healthcare professional for medical decisions.